Analysts expect that Healthequity Inc (NASDAQ:HQY) will post $69.76 million in sales for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Healthequity’s earnings, with the highest sales estimate coming in at $71.08 million and the lowest estimate coming in at $68.60 million. Healthequity reported sales of $56.79 million during the same quarter last year, which would suggest a positive year over year growth rate of 22.8%. The business is scheduled to issue its next earnings results on Tuesday, December 4th.
According to Zacks, analysts expect that Healthequity will report full year sales of $284.11 million for the current year, with estimates ranging from $282.80 million to $286.00 million. For the next year, analysts anticipate that the business will report sales of $347.53 million, with estimates ranging from $340.80 million to $358.59 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Healthequity.
Healthequity (NASDAQ:HQY) last announced its earnings results on Tuesday, September 4th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.22 by $0.12. The firm had revenue of $71.10 million for the quarter, compared to the consensus estimate of $69.84 million. Healthequity had a net margin of 23.81% and a return on equity of 12.58%. The business’s quarterly revenue was up 25.0% on a year-over-year basis. During the same period last year, the company posted $0.27 EPS.
Several brokerages have recently weighed in on HQY. Zacks Investment Research cut shares of Healthequity from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. KeyCorp raised their price target on shares of Healthequity from $82.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 19th. Citigroup reaffirmed a “buy” rating and set a $110.00 price target on shares of Healthequity in a research note on Wednesday, September 5th. Wells Fargo & Co raised their price target on shares of Healthequity from $84.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 5th. Finally, Cantor Fitzgerald raised their price target on shares of Healthequity from $68.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 5th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $93.08.
In related news, Director Frank Medici sold 6,904 shares of the firm’s stock in a transaction on Friday, July 13th. The shares were sold at an average price of $80.40, for a total value of $555,081.60. Following the completion of the transaction, the director now directly owns 17,649 shares of the company’s stock, valued at $1,418,979.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction on Thursday, September 20th. The shares were sold at an average price of $92.93, for a total transaction of $371,720.00. Following the completion of the transaction, the vice president now directly owns 96,100 shares of the company’s stock, valued at $8,930,573. The disclosure for this sale can be found here. Insiders sold 30,500 shares of company stock valued at $2,522,301 over the last three months. 4.00% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. Redwood Investments LLC bought a new position in Healthequity during the second quarter worth $12,188,000. S&CO Inc. bought a new position in Healthequity during the second quarter worth $204,000. Riverhead Capital Management LLC boosted its position in Healthequity by 3.9% during the second quarter. Riverhead Capital Management LLC now owns 18,829 shares of the company’s stock worth $1,414,000 after purchasing an additional 713 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Healthequity by 10.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 276,878 shares of the company’s stock worth $20,794,000 after purchasing an additional 26,635 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Healthequity by 4.0% during the first quarter. Principal Financial Group Inc. now owns 445,219 shares of the company’s stock worth $26,953,000 after purchasing an additional 17,193 shares during the period. 96.94% of the stock is owned by institutional investors and hedge funds.
HQY stock traded down $2.76 during mid-day trading on Friday, hitting $86.73. 10,703 shares of the company were exchanged, compared to its average volume of 618,960. The company has a market capitalization of $5.86 billion, a P/E ratio of 164.31, a price-to-earnings-growth ratio of 3.28 and a beta of 1.47. Healthequity has a 1-year low of $42.92 and a 1-year high of $99.99.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.